AVEO Oncology (AVEO) Misses Q1 EPS by 5c

AVEO Oncology (NASDAQ: AVEO) reported Q1 EPS of ($0.30), $0.05 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $20.9 million versus the consensus estimate of $20.65 million.

GUIDANCE:

AVEO Oncology sees FY2022 revenue of $100-110 million.

For earnings history and earnings-related data on AVEO Oncology (AVEO) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Beyond Air, Inc. (XAIR) Tops Q1 reported Q1 Revenue ; Offers Guidance
• Karyopharm Therapeutics (KPTI) Misses Q2 EPS by $1.01, Beats on Revenue; Offers FY26 Revenue Guidance